AMRX Stock Analysis: Buy, Sell, or Hold?
AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock
$17.91
0.01 (0.06%)
▲
5d:
-1.32%
30d:
-0.33%
90d:
+44.2%
HOLD
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When AMRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AMRX is fairly valued with market pricing in 4.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: AMRX is fairly valued with market pricing in 4.0% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$27.45
Based on 11.8% avg growth
INTRINSIC VALUE TODAY
$17.04
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.2x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AMRX is currently trading at $17.91, which is considered fair relative to its 30-day fair value range of $17.45 to $18.52. From a valuation perspective, the stock is trading at a premium (Forward PE: 14.9) compared to its historical average (13.2). At these levels, the market is pricing in 4.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AMRX is in a strong uptrend. Immediate support is located at $16.77, while resistance sits at $18.76.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.75 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AMRX is in a strong uptrend. Immediate support is located at $16.77, while resistance sits at $18.76.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $20.75 (+15.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.45 -
$18.52
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
Protect Your Profits
Holding AMRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($20.75)
- NEUTRAL: Market pricing in 4.0% annual earnings growth - fairly valued
- NEUTRAL: Bottoming setup forming (50/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$17.45 -
$18.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$16.77
Resistance Level
$18.76
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.92
Wall Street Target
$20.75
(+15.9%)
Revenue Growth (YoY)
9.9%
Earnings Growth (YoY)
157.1%
Profit Margin
5.1%
Valuation Premium vs History
+4.0% premium
PE vs Historical
14.9 vs 13.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$18.63
(+4%)
2-Year Target
$19.37
(+8%)
3-Year Target
$20.15
(+13%)
3-Yr Target (if PE normalizes)
(PE: 15→13)
PE COMPRESSION
$17.82
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 19.5%)
$41.11
(+130%)
Base:
(SPY PE: 14.9, Growth: 19.5%)
$30.57
(+71%)
Bear:
(PE: 12.7, Growth: 19.5%)
$25.98
(+45%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (38x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 38.09 | Current EPS (TTM): $0.47
Bull Case
$39.38
(+120%)
Analyst growth 100.0%, PE expands to 41.9
Base Case
$35.80
(+100%)
Market implied 100.0%, PE stable at 38.1
Bear Case
$12.17
(-32%)
Severe decline -20.0%, PE contracts to 32.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 10:29 AM ET
Data refreshes hourly during market hours. Next update: 11:29 AM
Data refreshes hourly during market hours. Next update: 11:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AMRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced AMRX Option Strategies
Professional options setups generated by AI based on today's AMRX price and gamma walls.
